Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772221 | 0.91 | SIRT6 (0.50) | SIRT6RAB9ABDKRB1ALDH1A1LMNA | |
| SCHEMBL1887396 | 0.82 | L3MBTL1 (0.52) | SIRT6ALDH1A1LMNAKMT2AL3MBTL1 | |
| SCHEMBL2725731 | 0.81 | KDM4E (0.46) | RAB9ABDKRB1ALDH1A1KMT2AACACB | |
| SCHEMBL31167254 | 0.81 | HDAC6 (0.53) | RAB9ABDKRB1ALDH1A1KMT2AACACB | |
| SCHEMBL590915 | 0.81 | L3MBTL1 (0.53) | SIRT6ALDH1A1LMNAL3MBTL1MAPT | |
| SCHEMBL13270422 | 0.79 | KDM4E (0.57) | RAB9ABDKRB1ALDH1A1KMT2AACACB | |
| SCHEMBL23727581 | 0.77 | MAPK1 (0.47) | RAB9AKMT2AACACBL3MBTL1MAPT | |
| SCHEMBL7298034 | 0.77 | ALDH1A1 (0.51) | ALDH1A1LMNAKMT2AMAPTMAPK1 | |
| SCHEMBL13634220 | 0.76 | ALDH1A1 (0.48) | SIRT6RAB9AALDH1A1LMNAKMT2A | |
| Methylpyrrolidone SCHEMBL27622825 | 0.76 | KMT2A (0.49) | SIRT6ALDH1A1LMNAKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | SIRT6 688/4885RAB9A 2408/4885BDKRB1 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.